Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943368 · ClinicalTrials.gov registry record · NA
Using Virtual Reality (VR) Models for Robotic Prostatectomy
A NA study of Prostate Cancer, sponsored by Ceevra.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
- 6
- Study locations
NCT03943368: Completed NA study of Prostate Cancer, sponsored by Ceevra.
NCT03943368 is a NA study of Prostate Cancer that has completed, run by Ceevra. The registered enrollment target is 92 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03943368, a NA study of Prostate Cancer, has completed, sponsored by Ceevra.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
- 6
- Study locations
Study Summary
A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic prostatectomy) and improved patient care.
Primary Outcome
PSA blood test measured at threshold of 0.1 at 3-6 and 18-24 months
Conditions Studied
Interventions
- DEVICE Ceevra Reveal
Study Locations (6)
California
- UCLA Urology - Los Angeles
- UC Irvine - Orange
Washington
- Swedish Urology Group - Seattle
- Swedish Medical Center - Seattle
Florida
- Mayo Clinic Florida - Jacksonville
New York
- Mount Sinai Health System - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2023-09-30 |
| Phase | NA |
What the finished NCT03943368 record still lists
NCT03943368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ceevra Reveal is the first listed.
NCT03943368 lists 6 locations in 4 states (California, Washington, Florida).
Frequently Asked Questions
What is clinical trial NCT03943368 about?
NCT03943368 is a clinical study titled "Using Virtual Reality (VR) Models for Robotic Prostatectomy". A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic prostatectomy) and improved...
What is the current status of trial NCT03943368?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2019-01-01. Estimated completion is 2023-09-30.
What conditions does trial NCT03943368 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03943368?
The interventions under investigation include: Ceevra Reveal (DEVICE).
Who is sponsoring clinical trial NCT03943368?
This trial is sponsored by Ceevra, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03943368 being conducted?
This trial has 6 study locations across California, Florida, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03943368's enrollment target sits among peer trials
92 353rd of 735 higher than 383 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI